Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin
- Conditions
- Interventions
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03826602
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Salt Lake City, Utah, United States
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT03786081
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
Effects of Tucatinib on Cardiac Repolarization in Healthy Participants
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT03777761
- Locations
- 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- Conditions
- Interventions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03723395
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT03722823
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
- Conditions
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT03657043
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸Ohio State University Clinical Trials Management Office, Columbus, Ohio, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT03646123
- Locations
- 🇺🇸
Texas Oncology - Flower Mound, Flower Mound, Texas, United States
🇺🇸Clinical Research Alliance - Abraham Mittelman, MD, LLC, Purchase, New York, United States
🇨🇿Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Other, Czechia
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT03582033
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center / University of Iowa, Iowa City, Iowa, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 692
- Registration Number
- NCT03485209
- Locations
- 🇺🇸
Shands Cancer Center / University of Florida, Gainesville, Florida, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Trial of Tisotumab Vedotin in Cervical Cancer
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03438396
- Locations
- 🇧🇪
UZLeuvenGynaecologische oncologie, Leuven, Belgium
🇺🇸UCLA Dept. of OBGYN, Los Angeles, California, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States